Zafrens is pioneering an ultra-high throughput platform to isolate, culture, image, and sequence millions of cells per day. The proprietary platform allows for full characterization of diverse cell populations, as well as directly correlating molecular profiles (DNA, RNA, protein) to cell phenotype and function.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/11/23 | $23,000,000 |
Alix Ventures BlueYard Capital FoundersX Ventures Global Brain Hawktail Iaso Ventures KOFA Healthcare Prime Movers Lab  | undisclosed |
